Search research articles
Contact Us
Filters
Showing results (151-160 of 175) with videos related to
Page
of 18
Sort By:
Gut
|
August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Digestive Diseases and Sciences
|
May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort
Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2024
Long-Term Outcomes of a Decentralized, Nurse-Led, Statewide Model of Care for Hepatitis C Among People in Prison in Victoria, Australia
Michael B MacIsaac, Timothy Papaluca, Lucy McDonald, et al.
Digestive Diseases and Sciences
|
May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
Paul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
Hepatology Communications
|
May 2, 2024
Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis
Natassia Tan, Natalie Ngu, Thomas Worland, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Trials
|
September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease
Leon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.
Journal of Crohn'S & Colitis
|
January 5, 2025
A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn's perianal fistulas
Michael De Gregorio, Leon S Winata, Imogen Hartley, et al.
Alimentary Pharmacology & Therapeutics
|
May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
Samuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
Simon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 175) with videos related to
Sort By:
Page
of 18
Gut
|
August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Digestive Diseases and Sciences
|
May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort
Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2024
Long-Term Outcomes of a Decentralized, Nurse-Led, Statewide Model of Care for Hepatitis C Among People in Prison in Victoria, Australia
Michael B MacIsaac, Timothy Papaluca, Lucy McDonald, et al.
Digestive Diseases and Sciences
|
May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
Paul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
Hepatology Communications
|
May 2, 2024
Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis
Natassia Tan, Natalie Ngu, Thomas Worland, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Trials
|
September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease
Leon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.
Journal of Crohn'S & Colitis
|
January 5, 2025
A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn's perianal fistulas
Michael De Gregorio, Leon S Winata, Imogen Hartley, et al.
Alimentary Pharmacology & Therapeutics
|
May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
Samuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
Simon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Page
of 18